SCHEMBL19745093

SCHEMBL19745093

OCC1CC2(CCC2)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26088513 0.94 APLNR (0.48)
SCHEMBL15090861 0.92 APLNR (0.46)
SCHEMBL10262814 0.88
SCHEMBL30458043 0.87 APLNR (0.42)
SCHEMBL3403066 0.82 APLNR (0.37)
SCHEMBL11317362 0.82 APLNR (0.58)
SCHEMBL3398871 0.80 APLNR (0.37)
SCHEMBL20825596 0.79 UGT2B7 (0.30)
SCHEMBL904100 0.79 APLNR (0.44)
SCHEMBL3398771 0.77 APLNR (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4667477-A2 PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE Gilead Sciences, Inc. (US) 2025-12-24 EP disclosed
WO-2025224262-A1 COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR MONTE ROSA THERAPEUTICS AG (CH) 2025-10-30 WO disclosed
EP-4192474-B1 PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE GILEAD SCIENCES INC (US) 2025-09-10 EP disclosed
EP-4608816-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF Monte Rosa Therapeutics AG (CH) 2025-09-03 EP disclosed
US-20250263395-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2025-08-21 US disclosed
US-12110305-B2 Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use GILEAD SCIENCES, INC. (US) 2024-10-08 US disclosed
US-20240317706-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2024-09-26 US disclosed
US-12084462-B2 Spiro bicyclic inhibitors of menin-MLL interaction JANSSEN PHARMACEUTICA NV (BE) 2024-09-10 US disclosed
EP-3873467-B1 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR MERCK SHARP & DOHME LLC (US) 2024-08-28 EP disclosed
US-20240229063-A1 TRANSGENIC CORN EVENT ZM_CSM63715 AND METHODS FOR DETECTION AND USES THEREOF MONSANTO TECHNOLOGY LLC (US) 2024-07-11 US disclosed
US-20210347762-A1 CARBOCYCLIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2021-11-11 US disclosed
US-11091465-B2 2021-08-17 US disclosed
EP-3512857-B1 SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2021-02-24 EP disclosed
US-20200385362-A1 CARBOCYCLIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2020-12-10 US disclosed
EP-3512857-A1 SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION Janssen Pharmaceutica NV (BE) 2019-07-24 EP disclosed
US-20190211036-A1 SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2019-07-11 US disclosed
US-20190202810-A1 CARBOCYCLIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2019-07-04 US disclosed
EP-3472151-A1 CARBOCYCLIC PROLINAMIDE DERIVATIVES ORION OPTHALMOLOGY LLC (US) 2019-04-24 EP disclosed
WO-2018050686-A1 SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2018-03-22 WO disclosed
WO-2017222914-A1 CARBOCYCLIC PROLINAMIDE DERIVATIVES INCEPTION 4, INC. (US) 2017-12-28 WO disclosed